About this trial
Patients who tear their ACL are at high risk for developing arthritis (post-traumatic osteoarthritis-PTOA) just 10 years later. Joint bleeding and inflammation contribute to deterioration of joint health. This study will determine whether treatment with Tranexamic Acid (TXA), an FDA approved medication that reduces bleeding right after ACL injury and reconstructive surgery reduces inflammation and improves joint health as a new strategy to prevent or delay the onset of PTOA.
Eligibility criteria
Qualifiers
age 18-30 years
within 4 days of unilateral ACL injury
presence of effusion/hemarthrosis.
Disqualifiers
inflammatory arthritis, radiographic osteoarthritis (K-L Grade 2 or higher), gout/ pseudogout
systemic or acute illness requiring medications
concomitant knee injury aside from meniscus tear and MCL tear not requiring surgery
prior surgery to either knee
Trial design
Treatments tested in this trial
- Tranexamic Acid
- Placebos
Treatment groups
Sponsors and collaborators
Stanford University
Lead sponsor
United States Department of Defense
Collaborator